Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery
详细信息 查看全文
- 作者：Songyang Wu ; Hao Liu ; Heng Zhang ; Chao Lin ; Ruochen Li ; Yifan Cao…
- 关键词：Gastric cancer ; Galectin ; 8 ; Prognosis ; Biomarker ; Overall survival ; Disease ; free survival
- 刊名：Tumor Biology
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：37
- 期：9
- 页码：12635-12642
- 全文大小：4,217 KB
- 刊物主题：Cancer Research;
- 出版者：Springer Netherlands
- ISSN：1423-0380
- 卷排序：37
文摘
The expression of galectin family has been unraveled in many malignant tumors and related with clinical outcomes. Our current study aims to investigate the prognostic value of galectin-8 expression and refine the current risk stratification system in non-metastatic gastric cancer patients. We retrospectively enrolled 421 patients with gastric cancer from Zhongshan Hospital, Fudan University in 2008. The expression of galectin-8 was detected by immunohistochemistry, and its association with clinicopathological features and prognostic outcomes were assessed. We found that galectin-8 expression was significantly associated with tumor size (P = 0.007), T stage (P = 0.001), N stage (P < 0.001), and tumor node metastasis (TNM) stage (P < 0.001). In addition, low galectin-8 expression indicated poor overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001). Furthermore, galectin-8 expression level was identified as an independent favorable prognostic factor for OS (P < 0.001). A predictive nomogram was generated with identified independent prognosticators to evaluate patient OS at 3 and 5 years. Our study suggested that galectin-8 is a potential independent favorable prognostic biomarker for survival and recurrence of patients with gastric cancer after surgical resection and the integration of intratumoral galectin-8 expression level into current TNM staging system would help to refine individual risk stratification.